Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.63 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398420 | 0.98 | S1PR1 (0.81) | S1PR1CYP2C9S1PR3S1PR5 | |
| SCHEMBL1398537 | 0.95 | S1PR1 (0.85) | S1PR1CYP2C9S1PR3S1PR5 | |
| SCHEMBL1981038 | 0.93 | S1PR1 (0.77) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398520 | 0.89 | S1PR1 (0.76) | S1PR1CYP2C9S1PR3S1PR5 | |
| SCHEMBL14039724 | 0.88 | S1PR1 (0.78) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398612 | 0.88 | S1PR1 (0.81) | S1PR1CYP2C9S1PR3S1PR5 | |
| SCHEMBL1398446 | 0.88 | S1PR1 (0.78) | S1PR1CYP2C9S1PR3S1PR5 | |
| SCHEMBL12600636 | 0.87 | S1PR1 (0.75) | S1PR1CYP2C9S1PR3S1PR5 | |
| SCHEMBL1398627 | 0.87 | S1PR1 (0.66) | S1PR1CYP2C9S1PR3S1PR5 | |
| SCHEMBL1398468 | 0.87 | S1PR1 (0.68) | S1PR1CYP2C9S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | claimed |
| EP-2513095-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-10-24 | — | — | EP | claimed |
| WO-2011072488-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-06-23 | — | — | WO | claimed |
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
| WO-2011072488-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885CYP2C9 3833/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.